Adaptive planning and toxicities of uniform scanning proton therapy for lung cancer patients
Open Access
- 1 January 2018
- journal article
- Published by Heighten Science Publications Corporation in Journal of Radiology and Oncology
- Vol. 2 (3), 055-061
- https://doi.org/10.29328/journal.jro.1001023
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- First Clinical Investigation of Cone Beam Computed Tomography and Deformable Registration for Adaptive Proton Therapy for Lung CancerEndocrine, 2016
- Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell lung cancerJournal of Radiation Research, 2014
- Clinical Implementation of Intensity Modulated Proton Therapy for Thoracic MalignanciesEndocrine, 2014
- Treatment of Non-Small Cell Lung Cancer Patients With Proton Beam-Based Stereotactic Body Radiotherapy: Dosimetric Comparison With Photon Plans Highlights Importance of Range UncertaintyEndocrine, 2012
- Toxicity and Patterns of Failure of Adaptive/Ablative Proton Therapy for Early-Stage, Medically Inoperable Non–Small Cell Lung CancerEndocrine, 2011
- Commissioning of output factors for uniform scanning proton beamsMedical Physics, 2011
- Dose–Volume Comparison of Proton Radiotherapy and Stereotactic Body Radiotherapy for Non-Small-Cell Lung CancerEndocrine, 2011
- Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: A dosimetric comparison with photon-based stereotactic body radiotherapyRadiotherapy and Oncology, 2010
- Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared With Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical StudyEndocrine, 2010
- Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non–small-cell lung cancerEndocrine, 2006